Semaglutide Research Dosage: Published Protocol Reference
Semaglutide dosage references vary by route and study context. The database lists Subcutaneous injection (diabetes): 0.25-1.0 mg, Once weekly, Subcutaneous injection (weight): 0.25-2.4 mg, Once weekly, and Subcutaneous injection (higher-dose weight): 7.2 mg maintenance, Once weekly. These are research-context references, not a universal protocol.
Direct Answer
Semaglutide remains the best-validated GLP-1-only agent: FDA-approved for diabetes, obesity, cardiovascular risk reduction, and now higher-dose Wegovy HD 7.2mg. Tirzepatide beats it on weight loss in direct obesity trials, but semaglutide still has the deepest cardiovascular outcomes record and the broadest GLP-1 evidence base.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Weight Loss & Metabolic
- Best for
- Obesity, type 2 diabetes, cardiovascular risk reduction in overweight patients
Research Dosage References
- <strong>Subcutaneous injection (diabetes)</strong> - 0.25-1.0 mg - Once weekly - Start at 0.25mg for 4 weeks, escalate to 0.5mg, then 1.0mg (Ozempic).
- <strong>Subcutaneous injection (weight)</strong> - 0.25-2.4 mg - Once weekly - Gradual escalation over 16-20 weeks to target dose of 2.4mg (Wegovy).
- <strong>Subcutaneous injection (higher-dose weight)</strong> - 7.2 mg maintenance - Once weekly - Wegovy HD 7.2mg was FDA-approved on March 19, 2026 for adults with obesity or overweight with at least one weight-related condition; titration follows the approved label.
- <strong>Oral</strong> - 3-14 mg - Once daily - Take on empty stomach with small amount of water. Wait 30 min before eating (Rybelsus).
Half-Life
~7 days (allowing once-weekly dosing).
Evidence Limits
Dosage entries are compiled from labels, published studies, and research-context references where available. For Semaglutide, the evidence grade is Level A, and the current research status is FDA Approved.
Safety Signals
- Boxed warning: thyroid C-cell tumors in rodents
- Contraindicated with personal/family history of medullary thyroid carcinoma
- Risk of pancreatitis
- May worsen diabetic retinopathy
- Not for use with insulin or other GLP-1 agonists
- Gallbladder events reported
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Weight Loss (Level A), Blood Sugar Control (Level A), Cardiovascular Protection (Level A), and GI Side Effects (Level A) |
| Primary citation count | 4 |
| Last reviewed | 2026-06-01 |
Related Guides
How to Cite This Page
ExaminePeptides. "Semaglutide Research Dosage: Published Protocol Reference." Last reviewed 2026-06-01. https://examinepeptides.com/answers/semaglutide-research-dosage/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.